Answers are grounded in this paper and cite their sources.
Assesses drug interactions and pharmacokinetics of bictegravir in HIV-1 treatment, suggesting improved safety profile.
drug-drug interaction (DDI) studies with M15 and M20 demonstrated that no clinically relevant interactions were expected.Overall, BIC is a novel and potent INSTI with a favourable resistance, PK, and ADME profile that provides important improvements over other currently available INSTIs for the treatment of HIV-1.
No takes yet. Share an insight, caveat, or question.
Subramanian et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: